| Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma | |
| Leng Yun; Qiu Lugui; Hou Jian; Zhao Yaozhong; Zhang Xuejun; Yang Shifang; Xi Hao; Huang Zhongxia; Pan Ling; Chen Wenming | |
| 刊名 | Chinese Journal of Cancer
 |
| 2016 | |
| 卷号 | 第35卷页码:P699-705 |
| 关键词 | Recombinant human circularly permuted TRAIL Phase II trial Relapsed or refractory multiple myeloma Efficacy Safety |
| ISSN号 | 1000-467X |
| URL标识 | 查看原文 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/1872031 |
| 专题 | 四川大学 |
| 作者单位 | Department of Hematology， Beijing Chao-Yang Hospital， Capital Medical University， Beijing， 100020；Department of Lymphoma Center， Institute of Hematology and Blood Diseases Hospital， C |
| 推荐引用方式 GB/T 7714 | Leng Yun,Qiu Lugui,Hou Jian,et al. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma[J]. Chinese Journal of Cancer,2016,第35卷:P699-705. |
| APA | Leng Yun.,Qiu Lugui.,Hou Jian.,Zhao Yaozhong.,Zhang Xuejun.,...&Chen Wenming.(2016).Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.Chinese Journal of Cancer,第35卷,P699-705. |
| MLA | Leng Yun,et al."Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma".Chinese Journal of Cancer 第35卷(2016):P699-705. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论